9,917 Shares in Bristol Myers Squibb Company $BMY Purchased by RHS Financial LLC

Key Points

• RHS Financial LLC has acquired 9,917 shares of Bristol Myers Squibb Company valued at approximately $459,000 during the second quarter.
• Several hedge funds have increased their stakes in the company, with Brighton Jones LLC boosting its position by 33.4% in the fourth quarter.
• Bristol Myers Squibb recently announced a quarterly dividend of $0.62 per share, resulting in a 5.6% yield for investors.

RHS Financial LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,917 shares of the biopharmaceutical company's stock, valued at approximately $459,000.

A number of other hedge funds also recently bought and sold shares of BMY. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. GAMMA Investing LLC raised its position in Bristol Myers Squibb by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company's stock worth $2,420,000 after buying an additional 6,267 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Bristol Myers Squibb by 1.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after buying an additional 869 shares during the last quarter. Focus Financial Network Inc. raised its position in Bristol Myers Squibb by 6.5% in the 1st quarter. Focus Financial Network Inc. now owns 4,068 shares of the biopharmaceutical company's stock worth $248,000 after buying an additional 248 shares during the last quarter. Finally, Krilogy Financial LLC raised its position in Bristol Myers Squibb by 8.5% in the 1st quarter. Krilogy Financial LLC now owns 10,941 shares of the biopharmaceutical company's stock worth $667,000 after buying an additional 856 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Citigroup decreased their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price for the company. in a research report on Tuesday, August 5th. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Dbs Bank raised Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $57.14.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.07% of the company's stock.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $44.01 on Monday. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33. The firm has a market capitalization of $89.57 billion, a P/E ratio of 17.74, a PEG ratio of 2.26 and a beta of 0.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company has a 50-day moving average price of $46.26 and a 200-day moving average price of $47.96.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the prior year, the firm earned $2.07 EPS. The business's revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.